Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review

References

• Rosenberg B, Vancamp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385–386.
   Google Scholar
• Einhorn LH, Williams SD. The role of cis-platinum in solid-tumor therapy. N Engl J Med. 1979;300:289–291.
   Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–584.
   Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
   Google Scholar
• Riddell IA. Cisplatin and oxaliplatin: our current understanding of their actions. Met Ions Life Sci. 2018;18:1–42.
   Google Scholar
• Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 2016;116:3436–3486.
   Google Scholar
• Davies MS, Berners-Price SJ, Hambley TW. Rates of platination of -AG- and -GA- containing double-stranded oligonucleotides: effect of chloride concentration. J Inorg Biochem. 2000;79:167–172.
   Google Scholar
• Berners-Price SJ, Frenkiel TA, Frey U, et al. Hydrolysis products of cisplatin: pK a determinations via[1H, 15N] NMR spectroscopy. J Chem Soc Chem Commun. 1992;10:789.
   Google Scholar
• Ober M, Lippard SJ. A 1,2-d(GpG) cisplatin intrastrand cross-link influences the rotational and translational setting of DNA in nucleosomes. J Am Chem Soc. 2008;130:2851–2861.
   Google Scholar
• Kuduk-Jaworska J, Jański JJ, Roszak S. Comparative study of hydrolytic and electron-driven processes in carboplatin biotransformation. J Inorg Biochem. 2017;170:148–159.
   Google Scholar
• Canovese L, Cattalini L, Chessa G, et al. Kinetics of the displacement of cyclobutane-1,1-dicarboxylate from diammine(cyclobutane-1,1-dicarboxylato)platinum(II) in aqueous solution. J Chem Soc Dalton Trans. 1988;2135. DOI:10.1039/dt9880002135.
   Google Scholar
• Fichtinger-Schepman AMJ, Van der Veer JL, Den Hartog JHJ, et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 1985;24:707–713.
   Google Scholar
• Takahara PM, Rosenzweig AC, Frederick CA, et al. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature. 1995;377:649–652.
   Google Scholar
• Cepeda V, Fuertes M, Castilla J, et al. Biochemical mechanisms of cisplatin cytotoxicity. ACAMC. 2007;7:3–18.
   Google Scholar
• Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9–23.
   Google Scholar
• Rébé C, Demontoux L, Pilot T, et al. Platinum derivatives effects on anticancer immune response. Biomolecules. 2019;10:13.
   Google Scholar
• Elferink F, van der Vijgh WJ, Klein I, et al. Pharmacokinetics of carboplatin after i.v. administration. Cancer Treat Rep. 1987;71:1231–1237.
   Google Scholar
• Los G, Verdegaal E, Noteborn HPJM, et al. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol. 1991;42:357–363.
   Google Scholar
• Schuler P, Trellakis S, Greve J, et al. In vitro chemosensitivity of head and neck cancer cell lines. Eur J Med Res. 2010;15:337–344.
   Google Scholar
• Moncharmont C, Auberdiac P, Mélis A, et al. Cisplatin or carboplatin, that is the question. Bull Cancer. 2011;98:164–175.
   Google Scholar
• Talley RW, O’Bryan RM, Gutterman JU, et al. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)–phase I clinical study. Cancer Chemother Rep. 1973;57:465–471.
   Google Scholar
• DeConti RC, Toftness BR, Lange RC, et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum(II). Cancer Res Am Assoc Cancer Res. 1973;33:1310–1315.
   Google Scholar
• Madias, Madias NE, Harrington JT, et al. Platinum nephrotoxicity. Am J Med. 1978;65:307–314. Elsevier.
   Google Scholar
• Hardaker WT, Stone RA, McCoy R. Platinum nephrotoxicity. Cancer. 1974;34:1030–1032.
   Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010;2:2490–2518.
   Google Scholar
• Crona DJ, Faso A, Nishijima TF, et al. A systematic review of strategies to prevent cisplatin‐induced nephrotoxicity. Oncologist. 2017;22:609–619.
   Google Scholar
• Rybak LP, Mukherjea D, Jajoo S, et al. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219:177–186.
   Google Scholar
• Alberts DS, Canetta R, Mason-Liddil N. Carboplatin in the first-line chemotherapy of ovarian cancer. Semin Oncol. 1990;17:54–60.
   Google Scholar
• Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-l,l-cyclobutanedicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9:140–147.
   Google Scholar
• Ho GY, Woodward N, Coward JIG. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol. 2016;102:37–46.
   Google Scholar
• Horwich A, Sleijfer DT, Fosså SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for research and treatment of cancer trial. JCO. 1997;15:1844–1852.
   Google Scholar
• Moeung S, Chevreau C, Broutin S, et al. Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumors: pharmacokinetic results of a phase II multicenter study. Clin Cancer Res. 2017;23:7171–7179.
   Google Scholar
• Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. JCO. 2003;21:3194–3200.
   Google Scholar
• Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non–small-cell lung cancer. JCO. 2004;22:3852–3859.
   Google Scholar
• Specenier P, Vermorken JB. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2018;18:901–915.
   Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–1883.
   Google Scholar
• Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res. 2005;11:6100–6102.
   Google Scholar
• Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 2000;20:645–652.
   Google Scholar
• Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994;94:703–708.
   Google Scholar
• Welsh C, Day R, McGurk C, et al. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer. 2004;110:352–361.
   Google Scholar
• Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst). 2004;3:1091–1101.
   Google Scholar
• Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997;57:1841–1845.
   Google Scholar
• Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087–3090.
   Google Scholar
• Nehmé A, Baskaran R, Nebel S, et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer. 1999;79:1104–1110.
   Google Scholar
• Cossa G, Gatti L, Zunino F, et al. Strategies to improve the efficacy of platinum compounds. CMC. 2009;16:2355–2365.
   Google Scholar
• Durant ST, Morris MM, Illand M, et al. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol. 1999;9:51–54.
   Google Scholar
• Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res Am Assoc Cancer Res. 1998;4:1–6.
   Google Scholar
• Chang AY, Wang M. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anti-Cancer Drugs. 2013;24:251–259.
   Google Scholar
• Zaanan A, Shi Q, Taieb J, et al. Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials. JAMA Oncol. 2018;4:379.
   Google Scholar
• Perego P, Robert J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. Cancer Chemother Pharmacol. 2016;77:5–18.
   Google Scholar
• Mohammed MQ, Retsas S. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anti-Cancer Drugs. 2000;11:859–863.
   Google Scholar
• Maung K, Chu E, Rothenberg M. Oxaliplatin combinations as first-line therapy in advanced colorectal cancer. Clin Colorectal Cancer. 2002;2:78–80.
   Google Scholar
• Alberti P. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol. 2019;15:487–497. Taylor & Francis.
   Google Scholar
• Ivanov AI, Christodoulou J, Parkinson JA, et al. Cisplatin binding sites on human albumin. J Biol Chem. 1998;273:14721–14730.
   Google Scholar
• Kato R, Sato T, Iwamoto A, et al. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometry. Biopharm Drug Dispos. 2019;40:242–249.
   Google Scholar
• Siddik ZH, Newell DR, Boxall FE, et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol. 1987;36:1925–1932.
   Google Scholar
• Reece PA, Stafford I, Abbott RL, et al. Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations. JCO. 1989;7:270–275.
   Google Scholar
• Vermorken JB, Vijgh WJFVD, Gall IK, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther. 1986;39:136–144.
   Google Scholar
• Daley-Yates PT, McBrien DC. The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid. Biochem Pharmacol. 1982;31:2243–2246.
   Google Scholar
• Reece PA, Stafford I, Russell J, et al. A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin. Cancer Chemother Pharmacol. 1987;20:26–32.
   Google Scholar
• Chatelut É. Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability. Bull Cancer. 2011;98:1253–1261.
   Google Scholar
• Burger H, Loos WJ, Eechoute K, et al. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011;14:22–34.
   Google Scholar
• Koepsell H, Endou H. The SLC22 drug transporter family. Pflügers Archiv Eur J Physiol. 2004;447:666–676.
   Google Scholar
• Surowiak P, Materna V, Kaplenko I, et al. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res. 2006;12:7149–7158.
   Google Scholar
• Terada T, Inui K. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol. 2008;75:1689–1696.
   Google Scholar
• Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319:879–886.
   Google Scholar
• Pabla N, Murphy RF, Liu K, et al. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296:F505–511.
   Google Scholar
• Sprowl JA, Ness RA, Sparreboom A. Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet. 2013;28:19–27.
   Google Scholar
• Wen X, Buckley B, McCandlish E, et al. Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol. 2014;184:1299–1308.
   Google Scholar
• Urien S, Brain E, Bugat R, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol. 2005;55:55–60.
   Google Scholar
• Jager NGL, Sari V, Westermann AM, et al. Full-dose cisplatin chemotherapy combined with hemodialysis in a patient with impaired renal function and a mediastinal germ cell tumor. Anticancer Drugs [Internet]. 2020 [cited 2020 Feb 11]. Available from: https://journals.lww.com/anti-cancerdrugs/Abstract/publishahead/Full_dose_cisplatin_chemotherapy_combined_with.98579.aspx
   Google Scholar
• Ezaki T, Matsumoto K, Morita S, et al. A case of gemcitabine and cisplatin chemotherapy in a patient with metastatic urothelial carcinoma receiving hemodialysis. Clin Genitourin Cancer. 2016;14:e413–6.
   Google Scholar
• Ma J, Verweij J, Kolker H, et al. Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. Br J Cancer. 1994;69:858–862.
   Google Scholar
• Calvert H, Judson I, van der Vijgh WJ. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv. 1993;17:189–217.
   Google Scholar
• Oguri S, Sakakibara T, Mase H, et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol. 1988;28:208–215.
   Google Scholar
• Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. JNCI. 1995;87:573–580.
   Google Scholar
• Delord J-P, Umlil A, Guimbaud R, et al. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol. 2003;51:127–131.
   Google Scholar
• Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs. 2003;14:817–824.
   Google Scholar
• Nikanjam M, Stewart CF, Takimoto CH, et al. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol. 2015;75:495–503.
   Google Scholar
• Fouladi M, Blaney SM, Poussaint TY, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors. Cancer. 2006;107:2291–2297.
   Google Scholar
• Deyme L, Barbolosi D, Gattacceca F. Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. Cancer Chemother Pharmacol. 2019;83:27–42.
   Google Scholar
• Moeung S, Chevreau S, Poinsignon V, et al. Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring. Ther Drug Monit. 2019;41:66–74.
   Google Scholar
• Ma J, Stoter G, Verweij J, et al. Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol. 1996;38:391–394.
   Google Scholar
• Johnsson A, Höglund P, Grubb A, et al. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemother Pharmacol. 1996;39:25–33.
   Google Scholar
• Giaccone G, González-Larriba JL, van Oosterom AT, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol. 2004;15:831–838.
   Google Scholar
• LeRoy AF, Wehling ML, Sponseller HL, et al. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med. 1977;18:184–191.
   Google Scholar
• Brouwers EEM, Tibben MM, Joerger M, et al. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Anal Bioanal Chem. 2005;382:1484–1490.
   Google Scholar
• Brouwers EEM, Tibben MM, Rosing H, et al. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom. 2006;41:1186–1194.
   Google Scholar
• Casetta B, Roncadin M, Montanari G, et al. Determination of platinum in biological fluids by ICP-mass spectrometry. At spectr. 1991;12:81–86.
   Google Scholar
• Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep. 1983;67:169–172.
   Google Scholar
• Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations. Am J Clin Oncol. 1985;8:77–80.
   Google Scholar
• Lagrange JL, Médecin B, Etienne MC, et al. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors. Pharmacotherapy. 1997;17:1246–1253.
   Google Scholar
• Nagai N, Kinoshita M, Ogata H, et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol. 1996;39:131–137.
   Google Scholar
• Nagai N, Ogata H, Wada Y, et al. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol. 1998;38:1025–1034.
   Google Scholar
• Hulin A, Royer B, Chatelut E, et al. Niveau de preuve du suivi thérapeutique pharmacologique du cisplatine. Therapies. 2010;65:151–155.
   Google Scholar
• Mense ES, Smit AAJ, Crul M, et al. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma. J Clin Pharm Ther. 2019;44:249–257.
   Google Scholar
• Jacobs C, Bertino JR, Goffinet DR, et al. 24-hour infusion of cis-platinum in head and neck cancers. Cancer. 1978;42:2135–2140.
   Google Scholar
• Erdlenbruch B, Nier M, Kern W, et al. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol. 2001;57:393–402.
   Google Scholar
• Ikeda K, Terashima M, Kawamura H, et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol. 1998;28:168–175.
   Google Scholar
• Reddel RR, Kefford RF, Grant JM, et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982;66:19–23.
   Google Scholar
• Lanvers‐Kaminsky C, Krefeld B, Dinnesen AG, et al. Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer. 2006;47:183–193.
   Google Scholar
• Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet. 1997;33:161–183.
   Google Scholar
• Egorin MJ, Thompson BW, Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1- cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984;44:5432–5438.
   Google Scholar
• Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. JCO Am Soc Clin Oncol. 1992;10:520–528.
   Google Scholar
• Schmitt A, Gladieff L, Laffont CM, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol. 2010;28:4568–4574.
   Google Scholar
• Kearns CM, Egorin MJ. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol. 1997;24:S2-91-S2-96.
   Google Scholar
• Calvert AH. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol. 1997;24:S2-85-S2-90.
   Google Scholar
• Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. JCO. 2007;26:85–90.
   Google Scholar
• Chevreau C, Thomas F, Couteau C, et al. Ototoxicity of high-dose carboplatin. J Clin Oncol. 2005;23:3649–3650. author reply 3650-3651.
   Google Scholar
• van Warmerdam L, Rodenhuis S, van der Wall E, et al. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer. 1996;73:979–984.
   Google Scholar
• Kloft C, Siegert W, Beyer J, et al. Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance. J Clin Pharmacol. 2002;42:762–773.
   Google Scholar
• Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990;25:299–303.
   Google Scholar
• Takimoto CH, Graham MA, Lockwood G, et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007;13:4832–4839.
   Google Scholar
• Chatelut E, Puisset F. The scientific basis of body surface area–based dosing. Clin Pharmacol Ther. 2014;95:359–361.
   Google Scholar
• Chatelut E, White-Koning ML, Mathijssen RH, et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer. 2012;107:1100–1106.
   Google Scholar
• de Jongh FE, Verweij J, Loos WJ, et al. Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure. JCO. 2001;19:3733–9.
   Google Scholar
• Eloxatin - FDA prescribing information, side effects and uses [Internet]. Drugs.com. [cited 2020 Feb 28]. Available from: https://www.drugs.com/pro/eloxatin.html
   Google Scholar
• Oxaliplatin 5mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2020 Feb 28]. Available from: https://www.medicines.org.uk/emc/product/6088/smpc
   Google Scholar
• OXALIPLATINE ARROW 5 mg/ml - Concentrate for solution for indusion- Summarry of product characteristics [Internet]. [cited 2020 Feb 28]. Available from: http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=65777819&typedoc=R
   Google Scholar
• Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205–1218.
   Google Scholar
• Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. 2000;45:157–164.
   Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. JCO. 1989;7:1748–1756.
   Google Scholar
• Egorin MJ, Reyno LM, Canetta RM, et al. Modeling toxicity and response in carboplatin-based combination chemotherapy. Semin Oncol. 1994;21:7–19.
   Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   Google Scholar
• Jelliffe RW. Letter: creatinine clearance: bedside estimate. Ann Intern Med. 1973;79:604–605.
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–470.
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   Google Scholar
• Janowitz T, Williams EH, Marshall A, et al. New model for estimating glomerular filtration rate in patients with cancer. JCO. 2017;35:2798–2805.
   Google Scholar
• Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26:294–305.
   Google Scholar
• Bénézet S, Guimbaud R, Chatelut E, et al. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients. Ann Oncol. 1997;8(6):607–609.
   Google Scholar
• Thomas F, Séronie-Vivien S, Gladieff L, et al. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet. 2005;44:1305–1316.
   Google Scholar
• Schmitt A, Gladieff L, Lansiaux A, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res. 2009;15:3633–3639.
   Google Scholar
• White-Koning M, Paludetto MN, Le Louedec F, et al. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance. Cancer Chemother Pharmacol. 2020;85:585–592. .
   Google Scholar
• Newell DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom children’s cancer study group. J Clin Oncol. 1993;11:2314–2323.
   Google Scholar
• Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–637.
   Google Scholar
• Patoux A, Bleyzac N, Boddy A, et al. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children. Eur J Clin Pharmacol. 2001;57:297–303.
   Google Scholar
• Bouvet Y, Bouissou F, Coulais Y, et al. GFR is better estimated by considering both serum cystatin C and creatinine levels. Pediatr Nephrol. 2006;21:1299–1306.
   Google Scholar
• Schwartz GJ, Schneider MF, Maier PS, et al. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int. 2012;82:445–453.
   Google Scholar
• Allen S, Wilson MW, Watkins A, et al. Comparison of two methods for carboplatin dosing in children with retinoblastoma. Pediatr Blood Cancer. 2010;55:47–54.
   Google Scholar
• Thomas H, Boddy AV, English MW, et al. Prospective validation of renal function–based carboplatin dosing in children with cancer: a United Kingdom children’s cancer study group trial. J Clin Oncol. 2000;18:3614–3621.
   Google Scholar
• Duong JK, Veal GJ, Nath CE, et al. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Br J Clin Pharmacol. 2019;85:136–146.
   Google Scholar
• Geoerger B, Doz F, Gentet J-C, et al. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol. 2008;26:4394–4400.
   Google Scholar
• Lam CG, Furman WL, Wang C, et al. Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. J Pediatr Hematol Oncol. 2015;37:e13–18.
   Google Scholar
• Hartmann C, Weinel P, Schmid H, et al. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. J Pediatr Hematol Oncol. 2011;33:344–349.
   Google Scholar
• Geoerger B, Chisholm J, Le Deley M-C, et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer. 2011;47:230–238.
   Google Scholar
• Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. JCO. 2000;18:1173–1180.
   Google Scholar
• Dubs A, Jacky E, Stahel R, et al. Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors. J Clin Oncol. 2004;22:1158.
   Google Scholar
• Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546–2552.
   Google Scholar
• Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer. 2000;36:264–269.
   Google Scholar
• Chevreau C, Massard C, Flechon A, et al. Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial. JCO. 2017;35:401.
   Google Scholar
• de Jonge M, Huitema A, Tukker A, et al. Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high-dose chemotherapy. Clin Pharmacol Ther. 2005;77:P94–P94.
   Google Scholar
• Monjanel-Mouterde S, Ciccolini J, Bagarry D, et al. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback. J Clin Pharm Ther. 2003;28:109–116.
   Google Scholar
• Salas S, Mercier C, Ciccolini J, et al. Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit. 2006;28:532–539.
   Google Scholar
• Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.
   Google Scholar
• Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open [Internet]. 2016;1. [cited 2020 Mar 27]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070272/
   Google Scholar
• Aronoff B, Berns, Brier, et al. Drug prescribing in renal failure. 5th ed. American College of Physicians Press; 2007.
   Google Scholar
• Tanabe N, Goto M, Morita H, et al. Pharmacokinetics of cis-diammine-dichlor-platin in a hemodialysis patient. Cancer Invest. 1991;9:629–635.
   Google Scholar
• Ribrag V, Droz J-P, Morizet J, et al. Test dose-guided administration of cisplatin in an anephric patient: A case report. Ann Oncol. 1993;4:679–682.
   Google Scholar
• Gorodetsky R, Vexler A, Bar-Khaim Y, et al. Plasma platinum elimination in a hemodialysis patient treated with cisplatin. Ther Drug Monit. 1995;17:203–206.
   Google Scholar
• Kurisu A, Hata T, Owada A. Full-dose chemotherapy for esophageal cancer patient under hemodialysis. Nephron. 2002;92:960.
   Google Scholar
• Watanabe R, Takiguchi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer. 2003;88:25–30.
   Google Scholar
• Amagai H, Murakami K, Sakata H, et al. Pharmacokinetics of cisplatin in an esophageal cancer patient on hemodialysis who was treated with a full-dose cisplatin-fluorouracil regimen: A case report. J Oncol Pharm Pract. 2019;25:1767–1775.
   Google Scholar
• Pouliquen A-L, Bousquet G, Le Maignan C, et al. Optimization of cisplatin doses in a testicular cancer patient with acute renal failure. J Oncol Pharm Pract. 2011;17:265–269.
   Google Scholar
• Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21:1395–1403.
   Google Scholar
• Gori S, Lunardi G, Inno A, et al. Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis. Clin Colorectal Cancer. 2014;13:260–263.
   Google Scholar
• van Berlo-van de Laar IRF, Brummelhuis WJ, Imholz ALT, et al. Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. J Clin Pharm Ther. 2018;43:574–577.
   Google Scholar
• Shitara K, Munakata M, Muto O, et al. Hepatic arterial infusion of oxaliplatin for a patient with hepatic metastases from colon cancer undergoing hemodialysis. Jpn J Clin Oncol. 2007;37:540–543.
   Google Scholar
• Wang D, Li X, Xu L, et al. Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report. Medicine (Baltimore). 2019;98:e17462.
   Google Scholar
• Maruta M, Miyoshi T, Matsuo N, et al. Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. J Chemother. 2020;1–5. DOI:10.1080/1120009X.2020.1728861.
   Google Scholar
• Chatelut E, Rostaing L, Gualano V, et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron. 1994;66:157–161.
   Google Scholar
• Motzer RJ, Niedzwiecki D, Isaacs M, et al. Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol. 1990;27:234–238.
   Google Scholar
• Guddati AK, Joy PS, Marak CP. Dose adjustment of carboplatin in patients on hemodialysis. Med Oncol. 2014;31:848.
   Google Scholar
• Rubie H, Doz F, Vassal G, et al. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy. Eur J Cancer. 2003;39:1433–1438.
   Google Scholar
• Veal GJ, Tilby MJ, Pearson ADJ, et al. Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Br J Cancer. 2007;96:725–731.
   Google Scholar
• Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. JCO. 2012;30:1034–1041.
   Google Scholar
• Veal GJ, Errington J, Hayden J, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015;51:2022–2030.
   Google Scholar
• Veal GJ, Errington J, Sastry J, et al. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. Cancer Chemother Pharmacol. 2016;77:685–692.
   Google Scholar
• Thomas F, Veal GJ, El Balkhi S, et al. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemother Pharmacol. 2018;82:361–365.
   Google Scholar
• Sebestyen J, Garg U, Lewing KB, et al. Cisplatin pharmacokinetics in a child receiving peritoneal dialysis. Pediatr Nephrol. 2010;25:1185–1189.
   Google Scholar
• Boucher AA, Mizuno T, Vinks AA, et al. Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. Pediatr Blood Cancer. 2019;66:e27425.
   Google Scholar
• Veal GJ, English MW, Grundy RG, et al. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemother Pharmacol. 2004;54:295–300.
   Google Scholar
• de Rouw N, Croes S, Posthuma R, et al. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Lung Cancer. 2019;130:156–158.
   Google Scholar
• Latz JE, Chaudhary A, Ghosh A, et al. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol. 2006;57:401–411.
   Google Scholar